We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Pharmasan Labs Inc. Wins Grant for Novel Immune Tolerance Test (ITT)-Cytokine Platform
News

Pharmasan Labs Inc. Wins Grant for Novel Immune Tolerance Test (ITT)-Cytokine Platform

Pharmasan Labs Inc. Wins Grant for Novel Immune Tolerance Test (ITT)-Cytokine Platform
News

Pharmasan Labs Inc. Wins Grant for Novel Immune Tolerance Test (ITT)-Cytokine Platform

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Pharmasan Labs Inc. Wins Grant for Novel Immune Tolerance Test (ITT)-Cytokine Platform "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The grant was awarded for the company's novel immune testing platform that aims to diagnose clinically relevant immune responses across a spectrum of acute and chronic conditions, thereby facilitating more targeted therapeutic interventions.

The ITT-Cytokine platform can help identify the root cause of chronic conditions, allowing practitioners to provide appropriate therapeutic interventions. As an example, Pharmasan Labs, Inc., in collaboration with NeuroScience, Inc., currently offers MY Lyme Immune I.D.™, which assesses whether an individual has had an immune response to the Lyme disease bacterium Borrelia burgdorferi and whether the infection is currently active.

"While Lyme disease, food sensitivity, and other conditions are often diagnosed using antibody-based methodologies, these traditional detection methods can sometimes yield false-negative results," remarked Mieke Kellermann, President of Pharmasan Labs, Inc. "By assaying for the presence of antigen-specific T cells and elevated cytokine production in response to specific antigens, we are identifying the key drivers of inflammation underlying clinical pathology and symptoms. Therefore, the ITT-Cytokine platform offers a superior diagnostic approach to antibody-based testing."
Advertisement